More info
Novel potent and selective CDK8/19 inhibitor, inhibiting MV4-11 leukemia growth in a systemic in vivo model with good tolerability, being more metabolically stable and providing a more sustained inhibition of CDK8/19-dependent cellular gene expression when comparing with the prototype inhibitor Senexin B